Noah Medical Corporation – FDA 483, Nov 26, 2024

The FDA Form 483 issued to BioAdvance Pharmaceuticals Inc., following an inspection conducted from March 4-15, 2024, details significant observations regarding non-compliance with Current Good Manufacturing Practice (CGMP) regulations, specifically 21 CFR Part 211 for finished pharmaceuticals. The document highlights several critical deficiencies in the company's quality management system. Key observations include a failure to adequately investigate deviations and out-of-specification (OOS) results, indicating a potential systemic weakness in root cause analysis and corrective action processes. Additionally, the inspection revealed inadequate validation of analytical methods employed for product release testing, which could compromise the assurance of product quality and potency. Deficiencies were also noted in the company's procedures for the handling and disposition of non-conforming materials, raising concerns about the potential for compromised or rejected materials entering the supply chain. Furthermore, the document cited shortcomings in the environmental monitoring programs within aseptic processing areas, which is crucial for preventing microbial contamination in sterile products. These findings collectively necessitate a robust response from BioAdvance Pharmaceuticals Inc. The regulatory framework ensures the safety, identity, strength, quality, and purity of pharmaceutical products. The FDA requires a comprehensive written response within 15 business days, outlining detailed corrective and preventive actions to address each observation and ensure sustained compliance.